KRAS and non-small cell lung carcinoma: This study aimed to evaluate the clinical efficacy and safety profile of KRAS<sup>G12C</sup> inhibitors (KGIs) compared with conventional chemotherapy regimens in patients with KRAS<sup>G12C</sup>-mutant NSCLC.<h4>Methods</h4>A comprehensive literature search was undertaken across six databases to identify phase 3 randomized controlled trials (RCTs) evaluating KGIs versus conventional chemotherapy.